Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
Eli Lilly & Co. director Ralph Alvarez reported acquiring additional common stock in the company. On 11/17/2025, he acquired 11.5 shares and 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share in two separate transactions. Following these transactions, Alvarez directly beneficially owns 55,378.773 shares of common stock and indirectly owns 758 shares through a trust. Some of the acquired shares were deferred as stock units under the Lilly Directors' Deferral Plan, to be settled in common stock after he separates from board service, aligning a portion of his director compensation with the company’s equity performance.
Lilly Endowment Inc., a 10% owner of Eli Lilly and Company (LLY), reported open-market sales of common stock. On November 17, 2025, it sold 7,789 shares at a weighted average price of $1,030.448 per share and 2,097 shares at a weighted average price of $1,031.526 per share, in multiple transactions within narrow price ranges. Following these sales, Lilly Endowment Inc. beneficially owned 92,872,191 shares of Eli Lilly common stock, held directly.
Eli Lilly & Co. (LLY) disclosed that a major shareholder reported multiple open-market sales of common stock on 11/14/2025. The transactions, all coded as sales, included blocks of 103,871, 55,908, 17,567, and 949 shares at weighted average prices between $1,030.00 and $1,033.39 per share. After these trades, the reporting person directly beneficially owned 92,882,077 Eli Lilly shares. The prices reported reflect weighted averages for multiple trades within the stated price ranges.
Eli Lilly & Co (LLY) executive filed an initial statement of beneficial ownership. As of 11/07/2025, the reporting officer (EVP, President LLY Imm) directly owned 3,725 shares of common stock.
The filing also lists restricted stock units (each RSU equals one common share) covering 391 shares with dates 02/16/2026, 2,530 shares with dates 11/01/2026, 394 shares with dates 02/16/2027, and 354.091 shares with dates 02/16/2028. Ownership is reported as direct.
Eli Lilly (LLY) reported insider sales on a Form 4. On 11/13/2025, the reporting person sold 45,246 shares of common stock at a weighted average price of $1,030.21, and 1,360 shares at a weighted average price of $1,031.777. The filing notes these were executed in multiple trades within the stated price ranges. Following the transactions, the reporting person beneficially owned 93,060,372 shares.
Eli Lilly (LLY) reported an insider transaction: the company’s SVP, Finance, & CAO sold 1,000 shares of common stock at $1,010.50 per share on November 13, 2025 (transaction code S).
The filing states the trade was made under a Rule 10b5-1 trading plan adopted on November 20, 2024. Following the sale, the reporting person beneficially owns 2,839.659 shares directly and 1,727.9 shares indirectly through a 401(k).
Eli Lilly (LLY) reported insider activity on a Form 4 showing multiple open‑market sales of common stock on 11/12/2025. The transactions were executed in several tranches at weighted‑average prices disclosed in footnotes.
Following the reported sales, the reporting person beneficially owned 93,106,978 shares, held directly. Footnotes note the sales occurred across price ranges from $1,001.213 to $1,021.661, with the reporting person able to provide detailed trade breakdowns upon request.
Lilly Endowment Inc. filed a Form 144 notice to sell 295,000 shares of Eli Lilly and Company (LLY) common stock. The filing lists an aggregate market value $300,245,100, an approximate sale date of November 13, 2025, execution through Fidelity Capital Markets, and trading on NYSE, NASDAQ.
The filing notes that 945,383,757 shares of Eli Lilly common stock are outstanding. The securities to be sold trace back to a gift acquired on 02/10/1948 from the J.K. Lilly Sr. Trust, with the donor’s acquisition dated 01/21/1937 and an original amount acquired of 38,400,000 shares.
Recent sales over the past three months are disclosed, including 305,000 shares for $308,411,211.50 on 11/12/2025 and 283,131 shares for $279,347,662.01 on 11/11/2025.
Eli Lilly (LLY): Insider transaction reported. A reporting person filed a Form 4 disclosing multiple open‑market sales of Eli Lilly common stock on November 11, 2025. Each line item is coded “S” for sale and reflects a weighted average price, with individual trades occurring within the disclosed ranges.
Reported weighted average prices spanned approximately $972.269 to $999.088, with footnotes stating underlying trade ranges from $972.00 to $999.49 per share across the listed transactions. Following these sales, the reporting person beneficially owned 93,411,978 shares, held directly.
Eli Lilly & Co (LLY) reported insider transactions on 11/10/2025. The reporting person executed three open-market sales: 12,864 shares at a weighted average price of $972.168 (range $972.00–$972.87); 3,887 shares at $973.626 (range $973.025–$973.95); and 118 shares at $974.089 (range $974.065–$974.14).
After these transactions, the reporting person beneficially owned 93,695,109 shares, held directly.